Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zentek Ltd. is a Canada-based nanotechnology company focused on the development and commercialization of graphene-based and nanomaterial-enabled products. The company operates at the intersection of advanced materials, healthcare, industrial applications, and environmental technologies, with an emphasis on applying proprietary graphene and aptamer technologies to real-world commercial problems. Zentek’s business model centers on intellectual property development, product validation, and strategic partnerships rather than large-scale manufacturing.
The company’s primary value drivers include its proprietary ZEN™ graphene-based technologies, most notably ZENGuard™, an antimicrobial coating platform, and its aptamer-based diagnostic and therapeutic research programs. Zentek serves customers and partners in healthcare, industrial filtration, personal protective equipment (PPE), and research markets. A key strategic advantage is its control of a high-purity graphite resource and its vertically integrated approach to graphene production, research, and application development. Founded in 2008 as a mineral exploration company, the firm evolved significantly after rebranding from Zen Graphene Solutions Ltd. to Zentek Ltd., reflecting its transition from resource development to applied nanotechnology commercialization.
Business Operations
Zentek operates through several core business lines focused on graphene-based materials, antimicrobial technologies, and biotechnology research. Revenue generation is currently centered on licensing, product partnerships, research contracts, and early-stage commercialization activities rather than large recurring product sales. The company maintains ownership of the Albany Graphite Deposit in Ontario, which is regarded as a strategic asset for future graphene supply, although it is not yet in commercial production.
A central operational focus is ZENGuard™, a graphene-based antimicrobial coating used in HVAC filters, PPE, and other surfaces, developed and validated through third-party testing and regulatory review. Zentek also operates a biotechnology arm through Triera Biosciences Inc., a wholly owned subsidiary, which develops aptamer-based diagnostic and therapeutic platforms. Operations are primarily research-driven, supported by collaborations with academic institutions, testing laboratories, and industrial partners in Canada and internationally.
Strategic Position & Investments
Zentek’s strategy prioritizes commercial validation of its technology platforms through regulatory approvals, licensing agreements, and strategic partnerships rather than capital-intensive manufacturing expansion. Growth initiatives focus on expanding applications for ZENGuard™ in air quality, healthcare, and industrial markets, as well as advancing aptamer-based technologies for diagnostics and drug development.
A major strategic investment was the acquisition of Triera Biosciences Inc., which significantly expanded Zentek’s footprint into biotechnology and life sciences. The company continues to invest in intellectual property development, regulatory testing, and pilot-scale production capabilities. Zentek is also involved in emerging sectors such as antimicrobial surface protection, nanomaterial-enabled filtration, and precision diagnostics, positioning itself as a technology provider rather than a single-product company.
Geographic Footprint
Zentek is headquartered in Canada, with its corporate offices and primary research activities based in Ontario. Its mineral asset, the Albany Graphite Deposit, is also located in Ontario, reinforcing the company’s domestic operational base. While the majority of employees and facilities are Canada-based, Zentek’s technologies are intended for global markets.
Internationally, the company maintains relationships with research institutions, testing organizations, and potential commercial partners across North America, Europe, and other global regions. Zentek’s geographic influence is primarily through intellectual property licensing, regulatory engagement, and collaborative research rather than direct overseas manufacturing or large physical operations.
Leadership & Governance
Zentek is led by an executive team with experience across materials science, biotechnology, and capital markets. Governance emphasizes disciplined capital allocation, intellectual property protection, and regulatory compliance, reflecting the company’s transition from exploration-stage origins to a technology commercialization focus.
Key members of leadership include:
- Greg Fenton – Chief Executive Officer
- Francis Dube – Executive Chairman
- Ian Smith – Chief Financial Officer
- Dr. Francis Dube – Chairman of the Board
- Dr. Anil Diwan – Director
Management has articulated a strategic vision centered on leveraging proprietary science into scalable commercial partnerships while maintaining long-term optionality through ownership of critical material resources and platform technologies.